BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin

被引:11
作者
Infante, M. [1 ]
Duran, M. [1 ]
Acedo, A. [1 ]
Perez-Cabornero, L. [1 ]
Sanz, D. J. [1 ]
Garcia-Gonzalez, M. [2 ]
Beristain, E. [3 ]
Esteban-Cardenosa, E. [4 ]
de la Hoya, M. [5 ,6 ]
Teule, A.
Vega, A. [7 ]
Tejada, M-I [3 ]
Lastra, E. [2 ]
Miner, C. [1 ]
Velasco, E. A. [1 ]
机构
[1] UVa CSIC, Grp Genet Canc, Inst Biol & Genet Mol, Valladolid 47003, Spain
[2] Hosp Gen Yague, Serv Oncol, Burgos, Spain
[3] Hosp Cruces, Genet Mol Lab, Dept Bioquim, Baracaldo, Spain
[4] Hosp Univ La Fe, Mol Biol Lab, Serv Biopatol Clin, Valencia, Spain
[5] Hosp Clin San Carlos, Oncol Mol Lab, Madrid, Spain
[6] Inst Salud Carlos III, Spanish Minist Sci & Innovat, Madrid, Spain
[7] CIBERER, FPGMX, SERGAS, Santiago De Compostela, Spain
关键词
BRCA1; BRCA2; breast cancer; founder mutations; ovarian cancer; BREAST-CANCER; HIGH PROPORTION; HETERODUPLEX ANALYSIS; PHENOTYPE ANALYSIS; HAPLOTYPE; POPULATION; IDENTIFICATION; FREQUENCY; RISKS; SPAIN;
D O I
10.1111/j.1399-0004.2009.01272.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer families varies among different populations, which typically present a wide spectrum of unique mutations. Splicing mutation 5272-1G > A of BRCA1 and frameshift mutation 5374delTATG of BRCA2 are highly prevalent mutations in Castilla-Leon (Spain), accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively. To test the presence of founder effects, 9 Spanish 5272-1G > A and 13 5374delTATG families were genotyped with polymorphic markers linked to BRCA1 or BRCA2. All the 5272-1G > A families shared a common haplotype in eight markers (1.1 Mb region) and the mutation age was estimated in 15 generations (similar to 380 years). A conserved haplotype associated to 5374delTATG was observed in four markers (0.82 Mb). The mutation occurred approximately 48 generations ago (similar to 1200 years). Each mutation likely arose from a common ancestor that could be traced to a small area of Castilla-Leon and expanded to other Spanish regions. They can have a significant impact on the clinical management of asymptomatic carriers as well as on the genetic screening strategy to be followed in populations with Spanish ancestries.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 50 条
  • [21] Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations
    Agalliu, Ilir
    Gern, Robert
    Leanza, Suzanne
    Burk, Robert D.
    CLINICAL CANCER RESEARCH, 2009, 15 (03) : 1112 - 1120
  • [22] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [23] BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela
    Lara, Karlena
    Consigliere, Nigmet
    Perez, Jorge
    Porco, Antonietta
    BIOLOGICAL RESEARCH, 2012, 45 (02) : 117 - 130
  • [24] Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer
    Torres-Mejia, Gabriela
    Royer, Robert
    Llacuachaqui, Marcia
    Akbari, Mohammad R.
    Giuliano, Anna R.
    Martinez-Matsushita, Louis
    Angeles-Llerenas, Angelica
    Ortega-Olvera, Carolina
    Ziv, Elad
    Lazcano-Ponce, Eduardo
    Phelan, Catherine M.
    Narod, Steven A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (03) : 498 - 505
  • [25] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [26] Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families
    Kang, Peter
    Mariapun, Shivaani
    Phuah, Sze Yee
    Lim, Linda Shushan
    Liu, Jianjun
    Yoon, Sook-Yee
    Thong, Meow Keong
    Taib, Nur Aishah Mohd
    Yip, Cheng Har
    Teo, Soo-Hwang
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) : 579 - 584
  • [27] Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1
    M. D. Miramar
    M. T. Calvo
    A. Rodriguez
    A. Antón
    F. Lorente
    E. Barrio
    A. Herrero
    J. Burriel
    A. García de Jalón
    Breast Cancer Research and Treatment, 2008, 112 : 353 - 358
  • [28] BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population
    Nielsen, Henriette Roed
    Nilbert, Mef
    Petersen, Janne
    Ladelund, Steen
    Thomassen, Mads
    Pedersen, Inge Sokilde
    Hansen, Thomas V. O.
    Skytte, Anne-Bine
    Borg, Ake
    Therkildsen, Christina
    FAMILIAL CANCER, 2016, 15 (04) : 507 - 512
  • [29] BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific
    Cifuentes-C, Laura
    Lucia Rivera-Herrera, Ana
    Barreto, Guillermo
    COLOMBIA MEDICA, 2019, 50 (03): : 163 - 175
  • [30] Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families
    Rudnicka, Helena
    Debniak, Tadeusz
    Cybulski, Cezary
    Huzarski, Tomasz
    Gronwald, Jacek
    Lubinski, Jan
    Gorski, Bohdan
    MOLECULAR BIOLOGY REPORTS, 2013, 40 (12) : 6619 - 6623